Alex Federico
No ORCID on file
· 1 paper in corpus
BACKGROUND: Most patients with ovarian cancer relapse within 2 years. Prospective randomized trials, such as DESKTOP III and SOC-I, have shown the role of secondary cytoreduction in improving oncological outcomes in selected patients, when …